Get the Stockscreener App
8.97
2.16%
0.19
Pre-market:
8.97
Olema Pharmaceuticals Inc stock is traded at $8.97, with a volume of 1.28M.
It is up +2.16% in the last 24 hours and down -8.38% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$8.78
Open:
$9.39
24h Volume:
1.28M
Relative Volume:
1.16
Market Cap:
$615.65M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-4.1721
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+11.71%
1M Performance:
-8.38%
6M Performance:
+73.84%
1Y Performance:
-22.20%
1-Day Range:
$8.97
$9.54
1-Week Range:
$8.10
$9.54
52-Week Range:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
8.97 | 602.61M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Sector ETF performance correlation with Olema Pharmaceuticals Inc.Portfolio Return Report & High Accuracy Swing Entry Alerts - newser.com
Forecasting Olema Pharmaceuticals Inc. price range with options dataJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
What Fibonacci levels say about Olema Pharmaceuticals Inc. reboundJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - newser.com
Is Olema Pharmaceuticals Inc. stock ready for breakoutVolume Spike & Risk Managed Trade Strategies - newser.com
How to build a dashboard for Olema Pharmaceuticals Inc. stockWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
Pier Capital LLC Has $3.29 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Why Olema Pharmaceuticals Inc. stock could rally in 2025July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock go up soonJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - newser.com
Can Olema Pharmaceuticals Inc. stock double in next 5 yearsMarket Activity Report & Smart Swing Trading Techniques - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap UpHere's Why - MarketBeat
How geopolitical tensions affect Olema Pharmaceuticals Inc. stockRate Hike & Daily Growth Stock Investment Tips - newser.com
Why Olema Pharmaceuticals Inc. stock is in analyst buy zoneQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
Olema Pharmaceuticals Inc. stock momentum explainedWeekly Stock Recap & Verified Entry Point Signals - newser.com
News impact scoring models applied to Olema Pharmaceuticals Inc.Bull Run & Free Long-Term Investment Growth Plans - newser.com
Will Olema Pharmaceuticals Inc. continue its uptrendGap Down & High Yield Equity Trading Tips - newser.com
Will Olema Pharmaceuticals Inc. stock rally after Fed decisions2025 Short Interest & Advanced Swing Trade Entry Plans - newser.com
Has Olema Pharmaceuticals Inc. found a price floorJuly 2025 Update & Trade Opportunity Analysis - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutWeekly Profit Analysis & AI Enhanced Trading Alerts - newser.com
Olema Pharmaceuticals, Inc. (OLMA) stock price, news, quote and history - Yahoo! Finance UK
Olema Pharmaceuticals to Present Phase 3 OPERA-02 Trial Details at SABCS 2025 - Quiver Quantitative
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 - The Manila Times
Olema (NASDAQ: OLMA) to present OPERA-02 Phase 3 palazestrant + ribociclib at SABCS 2025 - Stock Titan
Olema Pharmaceuticals welcomes new team to advance cancer therapies - Traders Union
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):